Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewTP 472N
说明： Negative control for TP 472
化学名： 1-(8-(2-(Cyclopropylmethoxy)phenyl)pyrrolo[1,2-a]pyrimidin-6-yl)ethanone
纯度： ≥98% (HPLC)
生物活性 for TP 472N
TP 472N is a negative control for TP 472. Inactive against other bromodomains (>20 μM against BRD9).
Active Analog also available.
许可信息
This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the TP 472 probe summary on the SGC website.
化合物库 for TP 472N
TP 472N is also offered as part of the Tocriscreen 2.0 Max and Tocriscreen Epigenetics Library. 了解 Tocris 化合物库的更多信息。
技术数据 for TP 472N
| 分子量 | 306.36 |
| 公式 | C19H18N2O2 |
| 储存 | Store at -20°C |
| 纯度 | ≥98% (HPLC) |
| CAS Number | 2080306-24-5 |
| PubChem ID | 124201853 |
| InChI Key | IDQWBZAMTQTECP-UHFFFAOYSA-N |
| Smiles | O=C(C)C1=CC(C2=CC=CC=C2OCC3CC3)=C4N=CC=CN41 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶解性数据 for TP 472N
| 溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
|---|---|---|---|
| 溶解性 | |||
| DMSO | 30.64 | 100 | |
| ethanol | 6.13 | 20 |
制备储备液 for TP 472N
以下数据基于产品分子量 306.36。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| 浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.26 mL | 16.32 mL | 32.64 mL |
| 5 mM | 0.65 mL | 3.26 mL | 6.53 mL |
| 10 mM | 0.33 mL | 1.63 mL | 3.26 mL |
| 50 mM | 0.07 mL | 0.33 mL | 0.65 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
产品说明书 for TP 472N
参考文献 for TP 472N
参考文献是支持产品生物活性的出版物。
If you know of a relevant reference for TP 472N, please let us know.
按标靶查看相关产品
按产品操作查看相关产品
关键词: TP 472N, TP 472N supplier, TP472N, Negative, control, TP, 472, Bromodomains, 5999, Tocris Bioscience
TP 472N 的评论
目前没有该产品的评论。 Be the first to review TP 472N and earn rewards!
Have you used TP 472N?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Stem Cell Research Product Guide
This product guide provides a background to the use of small molecules in stem cell research and lists over 200 products for use in:
- Self-renewal and Maintenance
- Differentiation
- Reprogramming
- Organoid Generation
- GMP and Ancillary Material Grade Products
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.